Interview with John Qiao, Founder & CEO of RadioClash By Caitlin Dolegowski, Marketing Manager, LSN
 John Qiao |
 Caitlin Dolegowski |
In this interview, we spoke with John Qiao, Founder and CEO of RadioClash, who secured third place in the Innovator’s Pitch Challenge at RESI Boston this past September. John shares insights into the company’s journey, their fundraising efforts, and their experience pitching to investors at the conference.
| Apply Pitch at RESI London | Apply Pitch at RESI JPM |
By Max Braht, Business Development Manager, LSN
Life Science Nation (LSN) furthered its dedication to medtech by exhibiting at the world’s largest med device conference, Advamed’s MedTech in Toronto from October 14th to the 17th. The only conclusion to be drawn from the 4350 attendees, 1926 companies/exhibitors/sponsors and 550 speakers/sessions is the industry is thriving and awash with optimism, innovation and a laser-focus on patients.
For LSN, the most exciting place was the Innovation Pavilion, featuring over 30 startups, some of which had found funding from past RESI events. From medical devices to diagnostics to combination products, we found an amazing variety of innovation from otoscopes that use ultrasound to determine if a pediatric ear infection requires antibiotics or not to a new generation of home dialysis machines that prevent the common problem of infections. We were happy to extend complimentary offers to use our deep knowledge in securing capital to help these companies to fund their developmental goals. If you’re a med device startup and need help fund raising, contact us at resi@lifesciencenation.com for a complimentary review of your pitch deck and free in-depth profile of an investor who is well-aligned with your company.
On the programming front, one of the keynotes featured tennis greats and one-time rivals Chris Evert and Martina Navratilova, who gave fascinating insights into their early lives as sports stars and their current battles against cancer, and how critical imaging devices are to their treatment. Advamed did not skimp on networking receptions, providing plentiful evening opportunities to connect over Canadian gastronomic specialties and leading entertainers.
Overall, the organizers reported that MedTech 2024 was a record-breaking event for them. We certainly felt the energy of the event and plan to return next year!
A venture capital firm with offices in US and Asia typically invests in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.
The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.
The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
A venture capital firm with offices in Europe actively invests in healthtech companies that address the global market. The firm typically invests in Seed and Series A rounds and can invest up to €5M, with additional capital reserved for follow-ons. The firm focuses on Europe-based companies.
The firm is currently seeking healthtech companies that are B2B focused. The firm has invested in therapeutics, medical device, and diagnostics companies in the past. The firm prefers to invest in companies who have a commercialized product with initial revenue and traction. The firm has been opportunistic towards indication.
The firm seeks to work with companies backed by an ambitious management team working on technologies with a highly scalable business model, and backed by strong IP. The firm seeks board representation in efforts to be an active partner of their portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
A venture capital firm with offices in the US looks to invest in diagnostics companies addressing gaps and answering problems present in the current market. The firm really looks to fund companies with a large market need. The firm invests exclusively in Seed to Series A rounds, with the ability for follow-on investments. The firm typically invests $1M-5M in the form of equity, with the ability to go up to $10M. The firm invests globally.
The firm is solely focused on diagnostics companies. The firm is indication- and modality- agnostic, and open to all classes of diagnostics. The firm can also invest in associated data tools; however, their focus lies in diagnostics companies. The firm invests in pre-commercial companies.
The firm typically co-invests. The firm likes to see management teams with diagnostic industry experience. The firm considers themselves “hands-on” investors, able to provide specific industry experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
A group of angel investors operates with a fund model with an average check size of USD $100K – $500K. The firm will both lead deals and will follow-on as well as syndicate with other angel groups. The majority of deals fall within the Seed-Series A range. The group only invests in U.S.-based C-Corps.
The firm is typically sector-agnostic in terms of technology and life science. Some members are more interested in early-stage Seed deals while others are looking for technologies that have been adequately de-risked.
The firm is looking for privately-held, technology-based companies with experienced management teams that can demonstrate strong execution skills, potential for market dominance, high growth, and a sustainable competitive advantage.
For deals where the firm would be acting as a co-investor, it is required that the round have a strong lead investor – i.e. one that actively negotiated the term sheet, represents a sizeable portion of the round, is taking an active role in the company (usually has a board seat) and has completed an internal due diligence effort and is willing to share the results of their due diligence effort with the firm members.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
RESI London is your gateway to global early-stage investment in life sciences. This video gives you a quick look at what to expect at the upcoming RESI London conference – the investor panels, Innovator’s Pitch Challenge, expert workshops, and partnering opportunities that unite startups and investors. Discover how RESI fosters meaningful connections in the life science ecosystem.
Next Phase Newsletter 